Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Omeros Corporation (OMER)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 964,922
  • Shares Outstanding, K 43,940
  • Annual Sales, $ 41,620 K
  • Annual Income, $ -66,750 K
  • 36-Month Beta 3.52
  • Price/Sales 23.06
  • Price/Cash Flow 0.00
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.63 +21.11%
on 07/07/17
25.64 -12.00%
on 06/26/17
-3.15 (-12.24%)
since 06/23/17
3-Month
13.56 +66.40%
on 05/11/17
27.09 -16.71%
on 06/22/17
+6.48 (+40.32%)
since 04/24/17
52-Week
7.20 +213.38%
on 10/18/16
27.09 -16.71%
on 06/22/17
+11.63 (+106.43%)
since 07/22/16

Most Recent Stories

More News
Today's Research Reports on Stocks to Watch: Sorrento Therapeutics and Omeros Corporation

NEW YORK, NY / ACCESSWIRE / July 17, 2017 / Sorrento Therapeutics had a big insider purchase revealed last week that helped drive share prices higher. Omeros Corporation also saw big gains after announcing...

SRNE : 2.10 (+2.44%)
OMER : 22.79 (+3.78%)
Top 5 Companies in the Pharmaceuticals Industry with the Best Relative Performance (OMER, SCMP, IPXL, CTLT, SUPN)

We looked at the Pharmaceuticals industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look...

SCMP : 10.95 (unch)
CTLT : 36.13 (+0.95%)
SUPN : 42.90 (+1.66%)
IPXL : 18.88 (+4.02%)
OMER : 22.79 (+3.78%)
Omeros (OMER) Hits New 52-Week High on Positive FDA Decision

Omeros Corporation (OMER) shares hit a new 52-week high of $22.80 on Thursday before eventually closing at $22.15.

VVUS : 1.22 (-1.61%)
GERN : 2.87 (+2.37%)
MEIP : 3.03 (+0.33%)
OMER : 22.79 (+3.78%)
Expansion of Global Clinical Trials for Treating an Array of Rare Diseases Boosting Market Growth

PALM BEACH, Florida, June 15, 2017 /PRNewswire/ --

VRX.TO : 21.72 (-1.27%)
NDRM : 38.38 (+15.60%)
VRX : 17.41 (-0.51%)
EPZM : 13.55 (+1.50%)
OMER : 22.79 (+3.78%)
MBRX : 1.88 (-1.57%)
Omeros (OMER) Lead Candidate Gets Breakthrough Designation

Omeros Corporation (OMER) announced that the FDA granted breakthrough therapy designation to pipeline candidate OMS721.

VVUS : 1.22 (-1.61%)
MEIP : 3.03 (+0.33%)
OMER : 22.79 (+3.78%)
ALXN : 131.53 (-0.20%)
Covered Call reports for Akamai Technologies, Cheesecake Factory, NVIDIA, Omeros and Tesla Motors include trade ideas that offer returns of up to 55%

InvestorsObserver issues critical PriceWatch Alerts for AKAM, CAKE, NVDA, OMER, and TSLA.

NVDA : 166.45 (-0.98%)
TSLA : 339.36 (+3.34%)
CAKE : 49.18 (-1.34%)
AKAM : 52.36 (+0.44%)
OMER : 22.79 (+3.78%)
FDA Grants Breakthrough Therapy Designation to Omeros' MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy

Omeros Corporation (NASDAQ: OMER) today announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of Immunoglobulin...

OMER : 22.79 (+3.78%)
Omeros (OMER) Worth a Look: Stock Adds 11.8% in Session

Omeros Corporation (OMER) shares rose almost 12% in the last trading session.

BIO : 232.26 (+0.29%)
OMER : 22.79 (+3.78%)
Omeros Announces OMS721 Presentation at 54th ERA-EDTA Congress

Omeros Corporation (NASDAQ: OMER) today announced that data from the company's Phase 2 clinical trial of OMS721 for the treatment of Immunoglobulin A (IgA) nephropathy and other kidney diseases...

OMER : 22.79 (+3.78%)
Blog Coverage: Omeros' Stock Jumped on Completion of IgA nephropathy Cohort and Additional Positive Results

Upcoming AWS Coverage on Halozyme Therapeutics Post-Earnings Results

HALO : 13.63 (+0.74%)
OMER : 22.79 (+3.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM)...

See More

Support & Resistance

2nd Resistance Point 22.87
1st Resistance Point 22.42
Last Price 22.79
1st Support Level 21.68
2nd Support Level 21.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.